JP2014520785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520785A5 JP2014520785A5 JP2014517816A JP2014517816A JP2014520785A5 JP 2014520785 A5 JP2014520785 A5 JP 2014520785A5 JP 2014517816 A JP2014517816 A JP 2014517816A JP 2014517816 A JP2014517816 A JP 2014517816A JP 2014520785 A5 JP2014520785 A5 JP 2014520785A5
- Authority
- JP
- Japan
- Prior art keywords
- amide
- hydroxy
- phenyl
- ethyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- QJJWMUZHTDQZDW-BDAKNGLRSA-N (1s,2s)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=C(F)C=C1 QJJWMUZHTDQZDW-BDAKNGLRSA-N 0.000 claims 3
- AHDDRJBFJBDEPW-BDAKNGLRSA-N (1s,2s)-2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-BDAKNGLRSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- WRSJNCVKPWFCPM-BDAKNGLRSA-N (1s,2s)-2-(3-fluorophenyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=CC(F)=C1 WRSJNCVKPWFCPM-BDAKNGLRSA-N 0.000 claims 2
- -1 -N (CH 3) 2 Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- KMDWBSGVKCYAMI-SQNIBIBYSA-N (1s,2s)-2-(3-fluorophenyl)-n-[(1r)-2-hydroxy-1-(6-propoxypyridin-3-yl)ethyl]cyclopropane-1-carboxamide Chemical compound C1=NC(OCCC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=C(F)C=CC=2)C1 KMDWBSGVKCYAMI-SQNIBIBYSA-N 0.000 claims 1
- FCJLCKFQVHVDLW-SQNIBIBYSA-N (1s,2s)-2-(4-fluorophenyl)-n-[(1r)-2-hydroxy-1-(6-propoxypyridin-3-yl)ethyl]cyclopropane-1-carboxamide Chemical compound C1=NC(OCCC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC(F)=CC=2)C1 FCJLCKFQVHVDLW-SQNIBIBYSA-N 0.000 claims 1
- BFSNFSYSCPYRIA-VYDXJSESSA-N (1s,2s)-n-[(1r)-1-(5-cyanopyridin-2-yl)-2-hydroxyethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2C[C@@H]2C(=O)N[C@@H](CO)C=2N=CC(=CC=2)C#N)=CC=CC=C1 BFSNFSYSCPYRIA-VYDXJSESSA-N 0.000 claims 1
- TXBPBRHPHHYZRS-QYZOEREBSA-N (1s,2s)-n-[(1r)-1-(6-cyclobutyloxypyridin-3-yl)-2-hydroxyethyl]-2-(3-fluorophenyl)cyclopropane-1-carboxamide Chemical compound C1([C@H]2C[C@@H]2C(=O)N[C@@H](CO)C=2C=NC(OC3CCC3)=CC=2)=CC=CC(F)=C1 TXBPBRHPHHYZRS-QYZOEREBSA-N 0.000 claims 1
- FCMRWVBXSWDTIB-QYZOEREBSA-N (1s,2s)-n-[(1r)-1-(6-cyclobutyloxypyridin-3-yl)-2-hydroxyethyl]-2-(4-fluorophenyl)cyclopropane-1-carboxamide Chemical compound C1([C@H]2C[C@@H]2C(=O)N[C@@H](CO)C=2C=NC(OC3CCC3)=CC=2)=CC=C(F)C=C1 FCMRWVBXSWDTIB-QYZOEREBSA-N 0.000 claims 1
- GQPZNMPEJNCEEQ-QYZOEREBSA-N (1s,2s)-n-[(1r)-1-(6-cyclobutyloxypyridin-3-yl)-2-hydroxyethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2C[C@@H]2C(=O)N[C@@H](CO)C=2C=NC(OC3CCC3)=CC=2)=CC=CC=C1 GQPZNMPEJNCEEQ-QYZOEREBSA-N 0.000 claims 1
- XGQNYRGXCSYGFF-IKGGRYGDSA-N (1s,2s)-n-[(1r)-1-(6-ethoxypyridin-3-yl)-2-hydroxyethyl]-2-(3-fluorophenyl)cyclopropane-1-carboxamide Chemical compound C1=NC(OCC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=C(F)C=CC=2)C1 XGQNYRGXCSYGFF-IKGGRYGDSA-N 0.000 claims 1
- PEULWTMISIJXOV-IKGGRYGDSA-N (1s,2s)-n-[(1r)-1-(6-ethoxypyridin-3-yl)-2-hydroxyethyl]-2-(4-fluorophenyl)cyclopropane-1-carboxamide Chemical compound C1=NC(OCC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC(F)=CC=2)C1 PEULWTMISIJXOV-IKGGRYGDSA-N 0.000 claims 1
- IPNHOTIKZDNVEY-IKGGRYGDSA-N (1s,2s)-n-[(1r)-1-(6-ethoxypyridin-3-yl)-2-hydroxyethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1=NC(OCC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC=CC=2)C1 IPNHOTIKZDNVEY-IKGGRYGDSA-N 0.000 claims 1
- VMXKGWVOHCYHGH-PMPSAXMXSA-N (1s,2s)-n-[(1r)-2-hydroxy-1-(6-methoxypyridin-3-yl)ethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1=NC(OC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC=CC=2)C1 VMXKGWVOHCYHGH-PMPSAXMXSA-N 0.000 claims 1
- CSWGEBRLGRWAQV-IKGGRYGDSA-N (1s,2s)-n-[(1r)-2-hydroxy-1-(6-methylpyridin-3-yl)ethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1=NC(C)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC=CC=2)C1 CSWGEBRLGRWAQV-IKGGRYGDSA-N 0.000 claims 1
- WETYIEWNKAHLTJ-SQNIBIBYSA-N (1s,2s)-n-[(1r)-2-hydroxy-1-(6-propan-2-yloxypyridin-3-yl)ethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1=NC(OC(C)C)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC=CC=2)C1 WETYIEWNKAHLTJ-SQNIBIBYSA-N 0.000 claims 1
- VVXVUTULNCJYCE-SQNIBIBYSA-N (1s,2s)-n-[(1r)-2-hydroxy-1-(6-propoxypyridin-3-yl)ethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1=NC(OCCC)=CC=C1[C@H](CO)NC(=O)[C@@H]1[C@@H](C=2C=CC=CC=2)C1 VVXVUTULNCJYCE-SQNIBIBYSA-N 0.000 claims 1
- LYODAGJMHSSYPP-ILXRZTDVSA-N (1s,2s)-n-[(1r)-2-hydroxy-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2C[C@@H]2C(=O)N[C@@H](CO)C=2C=NC(=CC=2)C(F)(F)F)=CC=CC=C1 LYODAGJMHSSYPP-ILXRZTDVSA-N 0.000 claims 1
- 229940124801 5-HT6 antagonist Drugs 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 208000022214 Post-traumatic amnestic disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 150000001975 deuterium Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 239000002400 serotonin 2A antagonist Substances 0.000 claims 1
- 239000003751 serotonin 6 antagonist Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000037221 weight management Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505847P | 2011-07-08 | 2011-07-08 | |
| US61/505,847 | 2011-07-08 | ||
| DKPA201100520 | 2011-07-08 | ||
| DKPA201100520 | 2011-07-08 | ||
| PCT/EP2012/063219 WO2013007621A1 (en) | 2011-07-08 | 2012-07-06 | Positive allosteric modulators of nicotinic acetylcholine receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015035219A Division JP5993472B2 (ja) | 2011-07-08 | 2015-02-25 | ニコチン性アセチルコリン受容体の陽性アロステリックモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520785A JP2014520785A (ja) | 2014-08-25 |
| JP2014520785A5 true JP2014520785A5 (enExample) | 2014-10-09 |
| JP5706043B2 JP5706043B2 (ja) | 2015-04-22 |
Family
ID=47505537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517816A Expired - Fee Related JP5706043B2 (ja) | 2011-07-08 | 2012-07-06 | ニコチン性アセチルコリン受容体の陽性アロステリックモジュレーター |
Country Status (37)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014006117A1 (en) | 2012-07-06 | 2014-01-09 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| CR20180452A (es) | 2016-03-22 | 2019-02-06 | Merck Sharp & Dohme | Moduladores alostéricos de receptores de acetilcolina nicotícos |
| RS66290B1 (sr) | 2018-05-01 | 2025-01-31 | Merck Sharp & Dohme Llc | Spiropiperidin alosterični modulatori nikotinskih acetiholinskih receptora |
| WO2021091751A1 (en) | 2019-11-05 | 2021-05-14 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
| GB202014080D0 (en) * | 2020-09-08 | 2020-10-21 | Neuro Bio Ltd | Down's syndrome |
| EP4404935A4 (en) * | 2021-09-21 | 2025-07-16 | Merck Sharp & Dohme Llc | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS |
| EP4404934A4 (en) * | 2021-09-21 | 2025-07-16 | Merck Sharp & Dohme Llc | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7144881B2 (en) * | 2002-11-22 | 2006-12-05 | Bristol-Myers Squibb Company | Arylcyclopropylcarboxylic amides as potassium channel openers |
| AP2007004157A0 (en) * | 2005-03-17 | 2007-10-31 | Pfizer | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain |
| CN101815512B (zh) * | 2007-10-04 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | 环丙基芳基酰胺衍生物和其用途 |
| MX2011012712A (es) * | 2009-05-29 | 2012-01-30 | Raqualia Pharma Inc | Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio. |
| US8497271B2 (en) * | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
-
2012
- 2012-06-07 UA UAA201400878A patent/UA111746C2/uk unknown
- 2012-07-06 BR BR122015016134-7A patent/BR122015016134A2/pt not_active IP Right Cessation
- 2012-07-06 RS RS20180732A patent/RS57400B1/sr unknown
- 2012-07-06 BR BR122015016135-5A patent/BR122015016135A2/pt not_active Application Discontinuation
- 2012-07-06 MD MDA20140001A patent/MD4634B1/ro not_active IP Right Cessation
- 2012-07-06 PL PL12740520T patent/PL2729447T3/pl unknown
- 2012-07-06 RU RU2014104372/04A patent/RU2604737C2/ru not_active IP Right Cessation
- 2012-07-06 PE PE2013002805A patent/PE20141184A1/es not_active Application Discontinuation
- 2012-07-06 SM SM20180328T patent/SMT201800328T1/it unknown
- 2012-07-06 DK DK12740520.7T patent/DK2729447T3/en active
- 2012-07-06 GE GEAP201213378A patent/GEP201606592B/en unknown
- 2012-07-06 CN CN201610982509.XA patent/CN107082760A/zh active Pending
- 2012-07-06 HU HUE12740520A patent/HUE038037T2/hu unknown
- 2012-07-06 RU RU2016144410A patent/RU2016144410A/ru not_active Application Discontinuation
- 2012-07-06 EP EP12740520.7A patent/EP2729447B1/en active Active
- 2012-07-06 KR KR1020147000425A patent/KR101928123B1/ko not_active Expired - Fee Related
- 2012-07-06 JP JP2014517816A patent/JP5706043B2/ja not_active Expired - Fee Related
- 2012-07-06 MX MX2014000015A patent/MX2014000015A/es unknown
- 2012-07-06 EP EP18163909.7A patent/EP3372582A1/en not_active Withdrawn
- 2012-07-06 EA EA201690237A patent/EA028832B1/ru not_active IP Right Cessation
- 2012-07-06 EA EA201490231A patent/EA024180B1/ru not_active IP Right Cessation
- 2012-07-06 MD MDA20160066A patent/MD4639C1/ro not_active IP Right Cessation
- 2012-07-06 SI SI201231330T patent/SI2729447T1/sl unknown
- 2012-07-06 AP AP2016009188A patent/AP2016009188A0/en unknown
- 2012-07-06 PH PH1/2014/500057A patent/PH12014500057A1/en unknown
- 2012-07-06 SG SG2013082631A patent/SG194838A1/en unknown
- 2012-07-06 AU AU2012283208A patent/AU2012283208B2/en not_active Ceased
- 2012-07-06 BR BR112013029146A patent/BR112013029146A2/pt not_active IP Right Cessation
- 2012-07-06 PE PE2015000595A patent/PE20151003A1/es active IP Right Grant
- 2012-07-06 TW TW101124401A patent/TWI538675B/zh not_active IP Right Cessation
- 2012-07-06 TR TR2018/09061T patent/TR201809061T4/tr unknown
- 2012-07-06 ES ES12740520.7T patent/ES2676396T3/es active Active
- 2012-07-06 LT LTEP12740520.7T patent/LT2729447T/lt unknown
- 2012-07-06 AP AP2014007403A patent/AP3793A/en active
- 2012-07-06 WO PCT/EP2012/063219 patent/WO2013007621A1/en not_active Ceased
- 2012-07-06 MY MYPI2013004039A patent/MY166463A/en unknown
- 2012-07-06 CN CN201610982508.5A patent/CN106966964A/zh active Pending
- 2012-07-06 AR ARP120102462A patent/AR087089A1/es unknown
- 2012-07-06 CN CN201280032481.3A patent/CN103764629B/zh not_active Expired - Fee Related
- 2012-07-06 CA CA2837529A patent/CA2837529C/en not_active Expired - Fee Related
- 2012-07-06 GE GEAP201713999A patent/GEP20176802B/en unknown
-
2013
- 2013-06-26 TW TW102122667A patent/TW201414730A/zh unknown
- 2013-06-26 TW TW102122669A patent/TWI592399B/zh not_active IP Right Cessation
- 2013-11-05 IL IL229271A patent/IL229271A/en active IP Right Grant
- 2013-11-11 CR CR20130583A patent/CR20130583A/es unknown
- 2013-12-27 CL CL2013003744A patent/CL2013003744A1/es unknown
-
2014
- 2014-01-07 ZA ZA2014/00110A patent/ZA201400110B/en unknown
- 2014-01-07 CO CO14001822A patent/CO6852071A2/es not_active Application Discontinuation
- 2014-01-20 EC ECSP14013158 patent/ECSP14013158A/es unknown
-
2015
- 2015-03-25 ZA ZA2015/02061A patent/ZA201502061B/en unknown
-
2017
- 2017-01-25 IL IL250286A patent/IL250286A0/en active IP Right Grant
- 2017-05-05 AU AU2017203014A patent/AU2017203014B2/en not_active Ceased
-
2018
- 2018-07-05 CY CY20181100705T patent/CY1120406T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520785A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| PH12012501773A1 (en) | Arylethynyl derivatives | |
| GEP20125621B (en) | 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor | |
| JP2014507455A5 (enExample) | ||
| CA2636324A1 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| JP2012523440A5 (enExample) | ||
| RU2014145682A (ru) | Органические соединения | |
| JP2012521994A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| RU2014104372A (ru) | Позитивные аллостерические модуляторы никотинового рецептора ацетилхолина | |
| JP2010523623A5 (enExample) | ||
| JP2012532125A5 (enExample) | ||
| WO2012101065A3 (en) | Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors | |
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| PH12013501895A1 (en) | Ethynyl derivatives as positive allosteric modulators of the mglur5 | |
| PH12014500775A1 (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| JP2017508733A5 (enExample) | ||
| JP2016028076A5 (enExample) | ||
| HRP20130918T1 (hr) | Derivati 4-aminopirimidina kao receptori antagonista histamina h4 | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| RU2011152516A (ru) | Производные 2-карбоксамид-7-пиперазинил-бензофурана 774 |